≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback
info icon

Malignant neoplasm of other endocrine glands and related structures, including Hilmo

Endpoint Browser

C3_ENDOCRINE_NAS_WIDE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — C75
  • Hospital discharge: ICD-9 — 194[1-9]
  • Hospital discharge: ICD-8 — 194[1-9]
  • Cause of death: ICD-10 — C75
  • Cause of death: ICD-9 — 194[1-9]
  • Cause of death: ICD-8 — 194[1-9]
  • Cancer registry: Topography ICD-O-3 — C75
  • Cancer registry: Morphology ICD-O-3 — ANY
  • Cancer registry: Behaviour codes — 3

3 out of 7 registries used, show all original rules.

182

4. Check minimum number of events

None

182

5. Include endpoints

None

182

6. Filter based on genotype QC (FinnGen only)

178

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

First used in FinnGen datafreeze
DF12

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 178 102 76
Unadjusted period prevalence (%) 0.04 0.04 0.03
Median age at first event (years) 56.96 51.20 64.68

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
182
Matched controls
1820
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
130
Kela drug reimbursment
Malignant tumour
+∞
57.4
52
*
H02AB02
ATC
dexamethasone; systemic
108.6
51.3
54
7
C75.0
ICD-10 Finland
Malignant neoplasm: Parathyroid gland
+∞
50.4
46
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
15.4
46.4
45
38
JN4BD
NOMESCO Finland
Extensive body CT
12.0
30.1
33
33
C75.9
ICD-10 Finland
Malignant neoplasm: Endocrine gland, unspecified
+∞
30.0
28
*
A03FA01
ATC
metoclopramide; systemic, rectal
6.5
29.6
63
138
XX3DW
NOMESCO Finland
Time consuming IT work
11.1
29.2
34
37
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
26.7
25
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
26.7
25
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
26.7
25
*
H02AB09
ATC
hydrocortisone; systemic
33.2
25.5
33
12
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
150.7
25.3
26
*
JN4AD
NOMESCO Finland
Body CT examination
9.4
25.1
33
42
8010/3-C75.0
ICD-O-3
Carcinoma, NOS, of parathyroid gland
+∞
24.5
23
*
H03AA01
ATC
levothyroxine sodium; systemic
4.8
24.1
82
264
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
44.9
22.4
27
7
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
22.3
21
*
C75.3
ICD-10 Finland
Malignant neoplasm: Pineal gland
+∞
22.3
21
*
Z51.5
ICD-10 Finland
Palliative care
9.3
21.5
28
35
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
20.2
19
*
WZC00
NOMESCO Finland
Treatment plan or consultation
4.2
20.1
88
334
C73.91
ICD-10 Finland
Papillary carcinoma of the thyroid gland (thyroid gland)
+∞
19.1
18
*
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
43.5
19.1
23
6
A04AA01
ATC
ondansetron; systemic, rectal
17.9
18.7
29
19
8260/3-C73.9
ICD-O-3
Papillary adenocarcinoma, NOS, of thyroid gland
+∞
18.0
17
*
E23.00
ICD-10 Finland
Panhypopituitarism
198.5
17.8
18
*
N02AA05
ATC
oxycodone; systemic
4.5
17.8
54
155
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
16.9
16
*
WX408
NOMESCO Finland
General anesthesy, balanced
3.9
16.9
69
245
BAA40
NOMESCO Finland
Unilateral lobectomy of thyroid gland
24.8
16.0
22
10
C75.1
ICD-10 Finland
Malignant neoplasm: Pituitary gland
+∞
15.9
15
*
115
Kela drug reimbursment
Breast cancer
+∞
15.9
15
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
14.8
14
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
14.8
14
*
8680/3-C75.5
ICD-O-3
Paraganglioma, NOS, of aortic body and other paraganglia
+∞
14.8
14
*
L03AA13
ATC
pegfilgrastim; parenteral
162.5
14.7
15
*
ZXE10
NOMESCO Finland
More than one and less than three hours
3.3
14.3
87
392
BBA40
NOMESCO Finland
Subtotal parathyroidectomy
58.1
14.1
16
*
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
37.2
13.8
17
5
101
Kela drug reimbursment
Anterior pituitary hypofunction
43.6
13.4
16
*
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
43.6
13.4
16
*
BBA30
NOMESCO Finland
Excision of lesion of parathyroid gland
75.3
12.8
14
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
12.6
12
*
C75.8
ICD-10 Finland
Malignant neoplasm: Pluriglandular involvement, unspecified
+∞
12.6
12
*
M05BX04
ATC
denosumab; parenteral
5.4
12.6
27
57
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
5.0
12.4
29
66
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
40.6
12.4
15
*
ZX120
NOMESCO Finland
Intravenous
5.3
12.3
27
58
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
18.0
11.9
18
11
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.6
11.9
48
165
E83.50
ICD-10 Finland
Hypercalcemia
24.9
11.8
16
7
C73
ICD-10 Finland
Malignant neoplasm of thyroid gland
+∞
11.6
11
*
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
+∞
11.6
11
*
116
Kela drug reimbursment
Prostate cancer
+∞
11.6
11
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
127.8
11.6
12
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
15.2
11.2
18
13
WZC30
NOMESCO Finland
Teaching
3.6
10.8
41
135
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.9
10.8
78
376
Z31.5
ICD-10 Finland
Genetic counselling
5.9
10.7
20
37
104
Kela drug reimbursment
Thyroid insufficiency
4.6
10.6
27
66
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
10.5
10
*
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
+∞
10.5
10
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
10.5
10
*
WF002
NOMESCO Finland
Radical radiotherapy
42.6
10.1
12
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.6
9.9
37
120
J38.0
ICD-10 Finland
Paralysis of vocal cords and larynx
18.8
9.6
14
8
D35.59
ICD-10 Finland
Other paragangliom
+∞
9.5
9
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
9.5
9
*
L01BC06
ATC
capecitabine; oral
+∞
9.5
9
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
9.5
9
*
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
+∞
9.5
9
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
13.5
9.0
15
12
ZXD10
NOMESCO Finland
Scheduled procedure
2.6
8.7
80
426
D44.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Thyroid gland
29.1
8.6
11
*
L03AA02
ATC
filgrastim; parenteral
94.2
8.5
9
*
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
+∞
8.4
8
*
C75.2
ICD-10 Finland
Malignant neoplasm: Craniopharyngeal duct
+∞
8.4
8
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
8.4
8
*
E21.3
ICD-10 Finland
Hyperparathyroidism, unspecified
15.4
8.3
13
9
ZXE00
NOMESCO Finland
One hour or less
2.5
8.3
84
466
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
9.6
8.2
16
18
L02BG04
ATC
letrozole; oral
13.9
8.0
13
10
R50.9
ICD-10 Finland
Fever, unspecified
3.0
7.7
39
151
ZXE20
NOMESCO Finland
More than three and less than five hours
3.2
7.6
34
123
WX402
NOMESCO Finland
General anaesthesia
2.8
7.6
47
204
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
83.3
7.5
8
*
HAC20
NOMESCO Finland
Total mastectomy
+∞
7.3
7
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
7.3
7
*
8272/3-C75.1
ICD-O-3
Pituitary carcinoma, NOS, of pituitary gland
+∞
7.3
7
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
+∞
7.3
7
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
7.3
7
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
+∞
7.3
7
*
YA1VG
NOMESCO Finland
MRI examination of head and neck with high intesity magnet for dose design of radiotherapy
+∞
7.3
7
*
C50.99
ICD-10 Finland
Breast, unspecified
+∞
7.3
7
*
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
+∞
7.3
7
*
E23.2
ICD-10 Finland
Diabetes insipidus
+∞
7.3
7
*
C75.5
ICD-10 Finland
Malignant neoplasm: Aortic body and other paraganglia
+∞
7.3
7
*
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
+∞
7.3
7
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
12.7
7.2
12
10
L02BA01
ATC
tamoxifen; oral
41.6
6.8
8
*
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
41.6
6.8
8
*
321
Kela drug reimbursment
Paricalcitol and cinacalcet
41.6
6.8
8
*
102
Kela drug reimbursment
Diabetes insipidus
41.6
6.8
8
*
E34.9
ICD-10 Finland
Endocrine disorder, unspecified
23.5
6.7
9
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
5.6
6.5
18
35
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
7.0
6.5
15
23
BB1BQ
NOMESCO Finland
Extensive scintigraphy of parathyroid gland, 2 isotopes, SPECT and low-dose CT
72.3
6.5
7
*
BBA20
NOMESCO Finland
Exploration of parathyroid gland
72.3
6.5
7
*
D35.1
ICD-10 Finland
Benign neoplasm: Parathyroid gland
72.3
6.5
7
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
6.3
6
*
L02BG06
ATC
exemestane; oral
+∞
6.3
6
*
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
+∞
6.3
6
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
6.3
6
*
L01AX03
ATC
temozolomide; systemic
+∞
6.3
6
*
Y77
ICPC
Malignant neoplasm prostate
+∞
6.3
6
*
C71.99
ICD-10 Finland
Malignant tumor in unspecified localization in the brain other or unspecified histology
+∞
6.3
6
*
C73, C75,
ICD-10 Finland
+∞
6.3
6
*
D35.50
ICD-10 Finland
Carotid body
+∞
6.3
6
*
ZX050
NOMESCO Finland
Stereotactic radiotherapy
+∞
6.3
6
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
6.3
6
*
C79.30
ICD-10 Finland
Secondary malignant tumor of the cerebrum
+∞
6.3
6
*
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
+∞
6.3
6
*
C74.0
ICD-10 Finland
Malignant neoplasm: Cortex of adrenal gland
+∞
6.3
6
*
C74.1
ICD-10 Finland
Malignant neoplasm: Medulla of adrenal gland
+∞
6.3
6
*
8140/3-C75.0
ICD-O-3
Adenocarcinoma, NOS, of parathyroid gland
+∞
6.3
6
*
WD205
NOMESCO Finland
Therapy of methastized malignancy with hormones
+∞
6.3
6
*
H05BX01
ATC
cinacalcet; oral
27.7
6.3
8
*
ZXC86
NOMESCO Finland
Use of endoscopic device
27.7
6.3
8
*
BA3AT
NOMESCO Finland
Cytology of thyroid with ultrasound quidance
13.1
6.2
10
8
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
13.1
6.2
10
8

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
52
40
17.80
57.01
1.6
1.2
—
—
—
0
0
106
444
4.32
21.38
10.6
2.9
7.40
7.40
ph
0.16
88
299
46
104
5.58
20.30
6.6
2.8
1.22
1.23
mmol/l
0.32
41
85
118
664
3.21
12.85
15.2
5.9
1.22
1.21
mmol/l
0.62
113
607
124
756
3.01
11.02
15.8
6.1
1.23
1.21
mmol/l
0.75
95
661
22
27
9.11
10.69
3.3
1.4
—
—
nmol/l
—
0
0
35
105
3.89
10.50
3.7
3.2
—
—
—
0
0
18
17
11.61
10.04
4.1
1.3
94.01
25.51
ng/l
0.54
18
17
36
114
3.69
9.97
9.4
3.1
112.73
85.05
ng/l
0.55
30
98
13
5
27.80
9.96
6.4
4.4
1.91
1.56
ug/l
—
13
5
17
38
4.83
7.35
3.3
2.4
7.41
7.41
ph
0.05
17
38
23
67
3.78
7.11
2.1
1.3
18.08
19.89
iu/l
0.10
17
57
15
22
7.33
6.67
3.1
3.3
5.49
10.62
pmol/l
1.16
15
22
25
82
3.38
6.48
9.4
8.4
24.85
24.98
mmol/l
0.07
25
82
82
493
2.21
6.29
2.2
1.6
—
—
—
0
0
31
122
2.86
5.92
1.5
1.1
—
—
—
0
0
54
287
2.25
5.49
2.6
2.7
480.84
528.18
mosm/kgh2o
0.95
49
247
16
34
5.06
5.45
2.6
1.4
6.47
6.48
u/l
—
10
26
128
1531
0.45
5.38
5.7
6.0
2.61
2.66
mmol/l
0.31
119
1436
126
1514
0.45
5.30
5.1
5.3
4.49
4.57
mmol/l
0.37
119
1422
95
634
2.04
5.29
7.2
3.7
34.69
36.16
g/l
1.37
89
596
125
1506
0.46
5.28
5.0
5.2
1.39
1.47
mmol/l
1.60
117
1406
116
1434
0.47
5.25
4.2
4.4
1.44
1.25
mmol/l
2.00
108
1323
8
6
13.86
5.13
2.4
1.5
57.13
58.50
nmol/l
—
8
6
12
20
6.34
5.00
3.6
1.7
8.78
8.10
kpa
0.61
12
20
12
20
6.34
5.00
3.6
1.7
4.85
4.74
kpa
0.19
12
20
12
20
6.34
5.00
3.5
1.7
2.36
2.52
mmol/l
—
7
10
98
692
1.90
4.36
14.6
15.2
1.21
1.29
inr
0.74
81
562
69
436
1.94
4.28
3.1
2.1
—
—
—
0
0
10
17
6.16
4.19
2.5
3.0
4.80
4.89
e9/l
—
10
17
73
475
1.90
4.12
6.6
4.7
—
—
—
0
0
95
675
1.85
4.04
19.1
9.1
0.00
0.00
e9/l
0.62
84
535
62
384
1.93
4.04
6.8
3.9
—
—
—
0
0
39
205
2.15
3.98
2.2
2.1
—
—
—
0
0
11
23
5.02
3.94
3.0
2.2
—
—
—
0
0
23
96
2.60
3.91
9.0
10.2
96.13
92.77
%
3.76
23
96
66
425
1.87
3.79
3.4
2.8
0.78
0.36
e6/l
0.41
56
296
27
126
2.34
3.64
10.0
8.9
—
—
—
0
0
90
646
1.78
3.57
3.5
2.5
—
—
estimate
—
0
0
73
494
1.80
3.52
3.7
2.9
78.65
181.97
e6/l
0.32
62
361
7
10
7.23
3.39
2.6
1.0
104.57
113.30
pmol/l
—
7
10
10
25
4.17
3.13
2.6
2.4
61.70
61.52
%
—
10
25
32
172
2.04
3.06
7.2
10.4
1.10
1.24
mmol/l
0.06
26
151
12
37
3.40
2.99
2.7
2.2
15.23
15.83
u/ml
0.06
12
29
52
341
1.73
2.69
5.7
4.2
—
—
—
0
0
105
829
1.63
2.64
19.0
5.8
4.21
4.29
e9/l
0.13
96
716
12
42
2.99
2.60
5.5
1.9
1.40
1.33
mg/l
0.11
12
35
31
175
1.93
2.59
7.5
10.3
7.43
7.42
ph
0.83
15
100
23
119
2.07
2.43
3.2
4.0
1.15
0.80
%
—
10
23
76
565
1.59
2.39
4.5
3.6
149.73
75.78
e6/l
0.65
63
376
7
17
4.24
2.38
6.1
1.4
3.37
219.86
u/ml
—
7
17
22
114
2.06
2.32
3.3
4.1
0.67
0.11
%
—
9
18
11
40
2.86
2.32
1.3
1.3
387.60
287.65
ug/g
—
5
19
6
13
4.73
2.29
1.8
1.2
—
—
—
0
0
154
1660
0.53
2.26
44.9
20.3
6.98
6.70
e9/l
1.05
149
1616
154
1660
0.53
2.26
44.7
20.3
4.41
4.51
e12/l
1.26
149
1617
33
199
1.80
2.25
1.4
1.2
—
—
—
0
0
30
176
1.84
2.23
8.1
3.5
7.37
7.39
ph
0.69
17
105
135
1158
1.64
2.23
16.1
5.3
91.69
76.12
u/l
2.02
130
1080
8
25
3.30
2.12
1.0
1.0
—
—
—
0
0
18
90
2.11
2.09
2.5
1.2
—
—
—
0
0
95
762
1.52
2.04
7.5
5.0
0.59
0.57
e9/l
0.47
85
643
56
402
1.57
1.99
1.7
1.4
—
—
—
0
0
95
768
1.50
1.93
7.5
5.0
0.04
0.04
e9/l
0.14
85
651
9
34
2.73
1.89
1.8
1.2
—
—
—
0
0
18
94
2.02
1.88
11.9
3.1
24.22
24.51
mmol/l
0.08
18
94
96
781
1.49
1.87
7.8
5.1
1.67
1.84
e9/l
1.39
88
684
21
117
1.90
1.83
3.4
4.2
0.13
0.00
%
—
8
16
60
445
1.52
1.82
11.5
4.4
—
—
—
0
0
149
1608
0.60
1.82
18.8
9.8
27.28
24.93
u/l
1.08
141
1555
7
23
3.12
1.82
1.1
1.3
—
—
—
0
0
11
47
2.43
1.81
1.7
1.3
7.23
2.96
ug/l
0.47
11
39
11
47
2.43
1.81
1.5
1.7
19.73
19.93
s
0.06
11
41
136
1497
0.64
1.78
5.7
5.1
5.93
5.97
mmol/l
0.17
125
1378
20
112
1.88
1.73
2.8
3.9
1.17
0.29
%
—
6
21
131
1450
0.66
1.71
7.6
6.9
41.09
39.87
mmol/mol
0.66
122
1373
96
793
1.45
1.67
8.7
5.2
0.16
0.20
e9/l
1.73
87
686
5
14
3.64
1.62
21.0
1.9
11.42
13.34
%
—
5
14
5
14
3.64
1.62
2.6
1.0
—
—
—
0
0
58
440
1.47
1.55
4.9
3.7
0.00
0.00
estimate
-0.00
28
141
33
224
1.58
1.47
2.3
2.5
136.90
97.25
ug/g
0.26
27
167
147
1574
0.66
1.35
25.7
12.2
—
—
—
0
0
22
139
1.66
1.30
2.6
1.9
70.80
65.96
e9/l
0.29
13
106
61
483
1.40
1.27
3.0
3.1
—
—
—
0
0
62
495
1.38
1.23
4.3
2.4
56.16
65.14
u/l
0.40
56
456
26
176
1.56
1.18
1.7
1.8
—
—
—
0
0
5
20
2.54
1.16
3.4
1.1
288.60
277.50
mosm/kgh2o
—
5
14
133
1207
1.38
1.11
8.8
4.3
15.45
14.77
pmol/l
2.21
128
1109
24
163
1.54
1.08
1.3
1.3
—
—
—
0
0
53
423
1.36
1.04
2.9
2.3
2.96
2.81
mg/l
0.21
47
361
30
217
1.46
1.02
2.1
1.6
—
—
—
0
0
5
23
2.21
0.98
1.6
1.2
—
—
—
0
0
5
23
2.21
0.98
1.0
1.0
—
—
—
0
0
9
152
0.57
0.93
1.8
1.8
—
—
—
0
0
7
127
0.53
0.92
2.6
2.5
—
12.98
—
0
11
9
147
0.59
0.83
1.8
1.7
—
0.00
estimate
—
0
34
34
263
1.36
0.81
3.0
2.5
108.17
1.22
e6/l
0.48
15
124
0
26
0.00
0.79
0.0
1.1
—
10.95
—
0
15
41
328
1.32
0.79
2.1
1.8
540.91
431.56
pmol/l
0.72
32
275
12
75
1.64
0.77
5.7
3.5
37.03
36.95
°c
0.45
12
75
14
92
1.57
0.75
10.4
2.5
0.56
0.60
%
0.29
14
92
6
110
0.53
0.74
1.2
1.3
—
29.73
—
0
12
46
378
1.29
0.73
3.7
2.3
349.11
342.92
umol/l
0.15
36
327
9
143
0.61
0.73
1.1
1.3
—
—
—
0
0
22
293
0.72
0.72
1.4
1.3
1.73
10.64
u/ml
—
9
113
14
93
1.55
0.72
10.4
2.5
1.14
1.32
%
0.24
14
93
13
85
1.57
0.71
1.1
1.3
—
—
—
0
0
15
102
1.51
0.70
1.2
1.3
—
—
—
0
0
24
313
0.73
0.69
1.4
1.3
14.29
36.27
iu/ml
—
7
100
137
1447
0.78
0.67
9.3
5.4
1.60
1.87
mu/l
1.74
129
1338
14
95
1.51
0.66
1.1
1.3
58.39
113.84
u/ml
—
8
39
85
759
1.22
0.66
4.5
3.0
221.63
113.12
ug/l
0.81
78
713
41
341
1.26
0.60
1.5
1.8
1.78
1.21
mg/l
0.45
26
274
13
89
1.50
0.60
4.8
9.3
—
—
—
0
0
0
22
0.00
0.59
0.0
1.1
—
—
—
0
0
8
55
1.48
0.57
1.4
1.1
—
—
—
0
0
33
269
1.28
0.56
2.2
2.0
—
—
—
0
0
9
59
1.55
0.56
1.0
1.2
—
—
—
0
0
34
279
1.27
0.55
2.3
1.7
1304.58
1121.99
nmol/l
0.38
24
222
20
155
1.33
0.49
2.4
1.5
—
—
—
0
0
6
93
0.63
0.43
2.2
3.5
1.02
1.02
ratio
—
6
88
51
573
0.85
0.42
3.9
3.5
—
—
—
0
0
0
16
0.00
0.41
0.0
1.0
—
—
—
0
0
0
17
0.00
0.41
0.0
1.3
—
—
—
0
0
92
856
1.15
0.39
4.6
3.7
0.00
0.00
estimate
-0.00
29
148
69
753
0.87
0.39
2.1
2.1
88.88
95.79
pmol/l
0.76
43
376
91
847
1.15
0.38
4.5
3.7
0.00
0.00
estimate
-0.00
32
156
12
90
1.36
0.37
1.9
2.6
—
—
—
0
0
5
78
0.63
0.36
1.8
1.8
—
—
—
0
0
35
398
0.85
0.33
1.2
1.4
0.80
1.80
u/ml
—
8
106
73
675
1.14
0.33
3.8
3.4
6.01
6.20
ph
0.78
43
376
12
152
0.77
0.31
1.9
2.5
3.52
7.50
ug/l
0.89
12
137
89
840
1.12
0.28
4.6
3.6
0.00
0.00
estimate
-0.00
31
158
60
644
0.90
0.25
5.0
3.9
29.15
87.94
ng/l
0.56
49
450
31
347
0.87
0.24
1.4
1.3
2.58
2.41
g/l
0.13
21
203
45
489
0.89
0.23
2.0
1.7
17.18
20.33
nmol/l
1.03
39
417
11
135
0.80
0.22
1.3
1.2
—
—
—
0
0
148
1513
0.88
0.22
26.4
13.5
26.13
22.38
mg/l
0.77
137
1211
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
127.35
—
0
10
0
12
0.00
0.21
0.0
1.2
—
15.68
—
0
12
0
13
0.00
0.21
0.0
1.1
—
0.49
—
0
8
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
3.0
—
14.11
—
0
9
0
14
0.00
0.20
0.0
1.6
—
70.57
—
0
14
5
67
0.74
0.17
1.6
1.8
—
—
—
0
0
8
68
1.18
0.17
1.3
1.2
—
—
—
0
0
8
70
1.15
0.16
8.4
2.7
—
—
—
0
0
110
1067
1.08
0.16
4.9
4.3
—
4.09
—
0
6
68
649
1.08
0.15
5.0
3.6
0.00
0.00
estimate
-0.00
28
125
69
662
1.07
0.13
1.9
2.0
1.57
1.31
mmol/l
1.40
53
569
50
479
1.06
0.09
4.1
3.1
0.00
0.00
estimate
-0.00
25
120
5
47
1.07
0.09
2.0
1.6
—
—
—
0
0
7
64
1.10
0.08
1.3
1.3
—
1.60
—
0
6
36
377
0.94
0.08
5.2
3.8
1.02
1.02
kg/l
0.97
23
241
61
594
1.04
0.06
3.6
3.4
7.95
7.60
mmol/l
0.19
50
512
16
169
0.94
0.03
1.3
1.5
—
—
—
0
0
20
191
1.05
0.03
2.1
1.6
—
—
—
0
0
57
561
1.02
0.02
4.0
3.5
111.95
44.38
mg/l
0.64
42
369
57
577
0.98
0.01
5.1
4.2
22.95
7.62
mg/mmol
0.85
39
368
12
119
1.01
0.00
1.2
1.2
—
—
—
0
0
25
249
1.00
0.00
3.6
2.7
0.77
0.76
ug/l
0.01
17
157
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
6.0
—
6.62
—
0
5
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.9
—
0.78
—
0
9
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
7.8
—
6.46
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
25.20
—
0
5
0
7
0.00
-0.00
0.0
1.7
—
3.16
—
0
7
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
30.67
—
0
9
5
49
1.02
-0.00
1.4
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
11.90
—
0
7

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: C3_ENDOCRINE_NAS_WIDE – Malignant neoplasm of other endocrine glands and related structures, including Hilmo

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).